Combination therapy based on artemisinins might not be the ideal treatment for malaria

A paper published in this month's PLoS Medicine suggests that combination therapy based on artemisinins (one of the newer antimalarial classes of drug) might not be the ideal treatment for uncomplicated malaria in Africa.

If used alone, artemisinins will cure the most severe type of malaria - falciparum malaria - in seven days. However, when used on their own, they have a high risk of the malaria coming back and hence must be combined with other antimalarials to work best.

Artemisinins may also slow down development of resistance to the partner drug. But although combinations including artemisinins have been widely advocated, they are expensive and relatively untested in areas where malaria is very frequent.

In a randomised trial conducted at four sites in Uganda, the researchers, led by Grant Dorsey from UCSF, showed that patients treated with a cheaper combination of drugs - amodiaquine and sulfadoxine-pyrimethamine - had at least as good a chance of preventing recurrent malarial infection (defined as either new infections or the previous infection returning) compared with patients treated with artemisinin-based combination therapy. In the sites that had the highest transmission rates the cheaper combination worked better.

The authors conclude that although artemisinin combinations offer great hope for Africa, the ideal combination regimen remains uncertain and cost is a problem. To compare the efficacy of the different therapies, bigger and longer controlled trials are needed in many different conditions.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug MED6-189 shows promise against drug-resistant malaria